| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Cue Biopharma, Inc.'s insiders have reduced their positions by a net 86,790 shares worth roughly $2.4M. In the past 30 days, 0 insiders bought and 3 sold.
All 3 insiders who sold still hold shares after their sales.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 694.9K | $14.50M | -11,087 | |
| Other | 116.7K | $2.43M | -1,844 | |
| VP | 47.8K | $997.5K | -1,144 | |
| Dir | 32.6K | $679.9K | - | |
| Other | 31.5K | $657.1K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Dec 31, 2019 | Christopher A Marlett | Director | Sell | 24,700 | $16.28 | $402,209.00 | -100% | |
| Dec 26, 2019 | Christopher A Marlett | Director | Sell | 36,647 | $17.20 | $630,351.91 | -4.5% | |
| Dec 19, 2019 | Christopher A Marlett | Director | Sell | 24,732 | $15.94 | $394,114.36 | -2.9% | |
| Jun 21, 2019 | Daniel R Passeri | CEO and President | Buy | 1,377 | $7.26 | $9,997.02 | +2.7% | |
| Jun 10, 2019 | Colin Sandercock | SVP, General Counsel and Sec | Buy | 16,938 | $7.83 | $132,658.34 | New | |
| Jun 6, 2019 | Daniel R Passeri | CEO and President | Buy | 3,000 | $6.90 | $20,700.00 | +6.3% | |
| Dec 31, 2018 | Christopher A Marlett | Director | Buy | 18,521 | $4.64 | $85,937.44 | +26.1% | |
| Dec 28, 2018 | Anthony Digiandomenico | Director | Buy | 7,000 | $4.62 | $32,340.00 | +14.0% | |
| Dec 27, 2018 | Anthony Digiandomenico | Director | Buy | 20,000 | $4.77 | $95,400.00 | +66.7% | |
| Dec 26, 2018 | Christopher A Marlett | Director | Buy | 19,647 | $4.29 | $84,285.63 | +38.2% |